cervix cancer
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Histological or cytological confirmed Cervix squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of Uterine Cervix; -tumor stages FIGO Ib - IVa; -WHO performance status 0 to 2; -Scheduled for primary curative radiotherapy (either or not combined with chemotherapy or hyperthermia); - willing to take adequate contraceptive measures during the study - The patient is willing and capable to comply with study procedures; - 18 years or older; -Have given written informed consent before patient registration; - no previous surgery to the Cervix; - no previous radiation to the Cervix;
Exclusion criteria
Exclusion criteria: recent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Tumor to background ratio of [18F] HX4 PET images. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: - Overlap fraction of (for example) >50% max regions (i) before and during treatment (ii) in the time series. - Define the optimal time point for HX4 imaging in Cervix cancer, based on the highest tumor to background ratio. - Determine if there is a relationship between the SUVmax, SUVmean or tumor to muscle ratio in comparison to the amount of osteopontin in the blood, circulating CA-IX in the blood or the degree and presence of tumor tissue markers. - Overlap fraction of (for example) >50% max regions between HX4-PET and FDG-PET pre-treatment or three months after treatment. - Correlation of the SUVmax, SUVmean and tumor to muscle ratio in the [18F] HX4 PET images in comparison to local tumor recurrence and survival. - Correlation of the SUVmax, SUVmean and tumor to muscle ratio in the [18F] HX4 PET images in comparison to Complete Remission rates at 3 months | — |
Countries
Netherlands
Outcome results
None listed